FORM 6-K

 

SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

 

Report of Foreign Issuer

 

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934


For period ending July 14, 2008

GlaxoSmithKline plc
(Name of registrant)

 

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)


Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F


Form 20-F x Form 40-F
 --


Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No x
  --

Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons


I give below details of an increase in interests in the Ordinary shares of GlaxoSmithKline plc in respect of the personal holdings of the under-mentioned persons at a price of £12.44 per Ordinary share, following the re-investment of the dividend paid to shareholders on 10 July 2008.

 

Mr A P Witty
25
Mrs C M Witty
334
Mr J S Heslop
337
Mrs P A Heslop
81
Mr D Learmouth
78
Dr D Pulman
151
Mrs C R Pulman
    50


The Company and the above named persons were advised of this information on 11 July 2008.


This notification relates to a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).



S M Bicknell

Company Secretary


14 July 2008

 

 

 

 


SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

 

                                                             GlaxoSmithKline plc
                                                                    (Registrant)

Date: July 14, 2008

                                                                                                        By: VICTORIA WHYTE
                                                                                                                                                                ------------------
                                                              Victoria Whyte
                                                 Authorised Signatory for and on
                                                   behalf of GlaxoSmithKline plc